Trials / Completed
CompletedNCT00070837
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (planned)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the highest dose of MLN2704 that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is taken up, broken down and eliminated by the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MLN2704 (DM1 conjugated monoclonal antibody MLN591) |
Timeline
- Start date
- 2003-10-01
- Completion
- 2004-10-01
- First posted
- 2003-10-13
- Last updated
- 2007-07-13
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00070837. Inclusion in this directory is not an endorsement.